Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Europe's Biopharma Sector Could Be In For Bumper Year

Executive Summary

The Belgian biotechs Ablynx and Galapagos are among the companies that are likely to have a very interesting 2018, according to analysts, and the sector in Europe as a whole is set for consolidation and more drugs getting to market, helped by a supportive regulatory landscape.


Related Content

Mid-level Player In A Big-league Market; Merck KGAA Plots A US Strategy Beyond Bavencio
AstraZeneca's Pipeline Reaps Rewards Of Return To Science
Shire Tempts Busch From Bayer As It Eyes Top Spot In Rare Diseases
Revamped Novartis In Good Shape At 3Q Ahead Of CEO Succession
Ipsen To File Cabozantinib For Liver Cancer In 1H 2018
Galapagos' FLORA: Highly Positive Hints In IPF, But More To Prove
Ipsen's New CEO Targets At Least One New Drug Annually 'Forever'


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts